New clinical study for children with AML aims to kill leukemia cells and minimize cardiac damage
- OPACC
- Dec 19, 2016
- 1 min read
Cooper is leading a new nationwide clinical trial, conducted within the Children's Oncology Group (COG), for children and adolescents with relapsed acute myelogenous leukemia (AML) to test a drug, CPX-351, which has been designed to kill leukemia cells while minimizing damage to the heart.
Comentarios